PathMaker Neurosystems completes ALS early feasibility study — presents at MDA Conference 2026
Summary
PathMaker Neurosystems announced completion of the early feasibility study for SynapDive — their non-invasive transcutaneous spinal cord stimulation system for ALS — with results presented at the 2026 MDA Clinical and Scientific Conference. The study evaluated both motor function preservation and respiratory support in ALS patients, targeting the dual threats of paralysis and respiratory failure that define disease progression. PathMaker is one of few neurotech companies specifically targeting ALS respiratory impairment.
Why it matters
ALS respiratory failure kills most patients within 2-5 years of diagnosis. A non-invasive neurostimulation system that preserves respiratory function alongside motor function would be genuinely disease-modifying for ALS — potentially extending ventilator-free survival significantly.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial